Barclays PLC Day One Biopharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 135,373 shares of DAWN stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,373

Previous 135,373 -0.0%

Holding current value

$1.72 Million

Previous $1.89 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$12.72 - $16.03 $1.01 Million - $1.28 Million	79,779 Added 143.5%	135,373 $1.89 Million
Q2 2024 Aug 14, 2024	SELL	$12.03 - $17.69 $142,820 - $210,015	-11,872 Reduced 17.6%	55,594 $765,000
Q1 2024 May 15, 2024	SELL	$13.56 - $17.46 $1.61 Million - $2.07 Million	-118,373 Reduced 63.7%	67,466 $1.11 Million
Q4 2023 Feb 15, 2024	BUY	$9.68 - $15.37 $522,303 - $829,319	53,957 Added 40.91%	185,839 $2.71 Million
Q3 2023 Nov 07, 2023	SELL	$11.22 - $14.86 $140,485 - $186,062	-12,521 Reduced 8.67%	131,882 $1.62 Million
Q2 2023 Aug 03, 2023	BUY	$11.74 - $14.47 $831,591 - $1.02 Million	70,834 Added 96.28%	144,403 $1.72 Million
Q1 2023 May 04, 2023	SELL	$12.75 - $23.41 $458,783 - $842,362	-35,983 Reduced 32.85%	73,569 $984,000
Q4 2022 Feb 13, 2023	BUY	$18.77 - $22.0 $358,938 - $420,706	19,123 Added 21.15%	109,552 $2.36 Million
Q3 2022 Nov 03, 2022	BUY	$16.44 - $26.57 $1.47 Million - $2.37 Million	89,257 Added 7615.78%	90,429 $1.81 Million
Q2 2022 Aug 12, 2022	SELL	$5.72 - $17.9 $24,681 - $77,238	-4,315 Reduced 78.64%	1,172 $21,000
Q1 2022 May 16, 2022	BUY	$9.12 - $17.47 $50,041 - $95,857	5,487 New	5,487 $55,000

Others Institutions Holding DAWN

# of Institutions

178

Shares Held

84M

Call Options Held

144K

Put Options Held

218K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $931M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account